| Onartuzumab studied in …STUDIED_INderived17 of 17show fewer |
|---|
| → studied in | NCT02488330Phase 3 · completed An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study · 17 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01632228Phase 2 · completed A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma · 17 trials list this drug (0 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01418222Phase 2 · completed FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer · 17 trials list this drug (0 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01068977Phase 1 · completed A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors · 17 trials list this drug (0 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00854308Phase 2 · completed A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib) · 17 trials list this drug (0 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02031731Phase 1 · completed The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors · 17 trials list this drug (0 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02031744Phase 3 · completed A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer · 17 trials list this drug (0 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01186991Phase 2 · completed Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer · 17 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01456325Phase 3 · completed A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) · 17 trials list this drug (0 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01662869Phase 3 · completed A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer · 17 trials list this drug (0 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01887886Phase 3 · completed A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation · 17 trials list this drug (0 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01897038Phase 1 · completed A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma · 17 trials list this drug (0 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01974258Phase 1 · withdrawn Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients · 17 trials list this drug (0 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01496742Phase 2 · completed A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer · 17 trials list this drug (0 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01519804Phase 2 · completed A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer · 17 trials list this drug (0 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01590719Phase 2 · completed A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer · 17 trials list this drug (0 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02044601Phase 1/Phase 2 · withdrawn Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) · 17 trials list this drug (0 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |